Literature DB >> 11387282

Prophylactic salpingectomy does not impair the ovarian response in IVF treatment.

A Strandell1, A Lindhard, U Waldenström, J Thorburn.   

Abstract

To examine the effect of prophylactic salpingectomy in patients with hydrosalpinges on the ovarian response to stimulation prior to IVF, 26 patients were included in a study in which they acted as their own controls. They were all part of a randomized controlled study, in which they had been randomized to no surgical intervention prior to IVF. After one or two failed cycles, they underwent laparoscopic uni- or bilateral salpingectomy of their diseased tubes. The cycles before and after surgery were compared and the ovarian response was assessed as the dose and duration of gonadotrophins and the number of retrieved and fertilized oocytes. There were no significant differences in any of the measured outcomes. The increasing age between cycles did not influence the ovarian response, assessed by a comparison with two matched control groups from the same original study; 46 patients salpingectomized before IVF and 25 patients without surgery. It is concluded that removal of hydrosalpinx as a prophylactic laparoscopic procedure does not compromise ovarian function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11387282     DOI: 10.1093/humrep/16.6.1135

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Ovarian response to gonadotropin stimulation in repeated IVF cycles after unilateral salpingectomy.

Authors:  Joseph Tal; Yoav Paltieli; Roman Korobotchka; Genia Ziskind; Izu Eibschitz; Gonen Ohel
Journal:  J Assist Reprod Genet       Date:  2002-10       Impact factor: 3.412

2.  Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma.

Authors:  Collette R Lessard-Anderson; Kathryn S Handlogten; Rochelle J Molitor; Sean C Dowdy; William A Cliby; Amy L Weaver; Jennifer St Sauver; Jamie N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

3.  Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate.

Authors:  J Vorwergk; M P Radosa; K Nicolaus; N Baus; J Jimenez Cruz; M Rengsberger; M Gajda; H Diebolder; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-27       Impact factor: 4.553

Review 4.  Surgical treatment for tubal disease in women due to undergo in vitro fertilisation.

Authors:  Neil Johnson; Sabine van Voorst; Martin C Sowter; Annika Strandell; Ben Willem J Mol
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review.

Authors:  Akira Iwase; Tomoko Nakamura; Tatsuo Nakahara; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Biol Endocrinol       Date:  2014-12-15       Impact factor: 5.211

Review 6.  Salpingectomy before assisted reproductive technologies: a systematic literature review.

Authors:  Marco Noventa; Salvatore Gizzo; Carlo Saccardi; Shara Borgato; Amerigo Vitagliano; Michela Quaranta; Pietro Litta; Michele Gangemi; Guido Ambrosini; Donato D'Antona; Stefano Palomba
Journal:  J Ovarian Res       Date:  2016-11-03       Impact factor: 4.234

7.  Opportunistic bilateral salpingectomy during benign gynecological surgery for ovarian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics and Gynecology.

Authors:  Mikio Mikami; Satoru Nagase; Wataru Yamagami; Kimio Ushijma; Hironori Tashiro; Hidetaka Katabuchi
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

8.  Salpingectomy may decrease antral follicle count but not live birth rate for IVF-ET patients aged 35-39 years: a retrospective study.

Authors:  Tong Chen; Feiyan Zhao; Qin Wang; Chang Liu; Yonglian Lan; Shuyu Wang; Zhimin Xin; Xiaokui Yang
Journal:  J Ovarian Res       Date:  2020-07-20       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.